Janos Tanyi, MD
Gynecologic Oncology · Philadelphia, PANPI 1649433319
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (37.7%), education and consulting fees — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 70.8% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $3,055, more than ten times the $13 reported in 2021.
Across 10 payments — averaging $310.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$2K
- On Target Laboratories, Inc$750
- Merck$107
- Eisai Inc.$36
- Medical Device Business Services, Inc.$13
Across 5 payments — averaging $45,199 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$177K
- AbbVie$35K
- Adaptimmune LLC$11K
- Pfizer$3K
What the payments were for
- Consulting fees$75024%
- Travel & lodging$1,17038%
- Food & beverage$1856%
- Education$1,00032%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 6 | $2,198 |
| On Target Laboratories, Inc | 1 | $750 |
| Merck | 1 | $107 |
| Eisai Inc. | 1 | $36 |
| Medical Device Business Services, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$1,151
- DAVINCI XI$1,000
- Cytalux$750
- KEYTRUDA$107
How this compares
$3,105 in reported general payments places this provider in the 65th percentile of 90 gynecologic oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Megestrol Acetate | 12 | $465 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Philadelphia
- Emily KoPhiladelphia$78K
- Anna SmithPhiladelphia$77K
- Robert BurgerPhiladelphia$59K
- Stephanie KingPhiladelphia$17K
- Sarah KimPhiladelphia$14K
- Fiona SimpkinsPhiladelphia$11K
- Ashley HaggertyPhiladelphia$8K
- Lea MoukarzelPhiladelphia$3K
- Charlotte MarcusPhiladelphia$660
- Camille McCallisterPhiladelphia$466
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.